Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.

Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ.

Clin Cancer Res. 2009 Jan 1;15(1):390-9. doi: 10.1158/1078-0432.CCR-08-0783.

2.

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A.

J Immunother. 2008 Apr;31(3):294-309. doi: 10.1097/CJI.0b013e31816a8910.

3.

A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.

Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS.

Clin Cancer Res. 2006 May 1;12(9):2817-25.

4.

Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).

Schumacher LY, Vo DD, Garban HJ, Comin-Anduix B, Owens SK, Dissette VB, Glaspy JA, McBride WH, Bonavida B, Economou JS, Ribas A.

J Immunol. 2006 Apr 15;176(8):4757-65.

5.

Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice.

Ribas A, Vo DD, Weeks DL, Comin-Anduix B, Schumacher LY, Garban HJ, McLean C, Yang J, Dissette VB, Peraza P, Owens SK, McBride WH, Glaspy JA, Economou JS.

Cancer Immunol Immunother. 2006 Jun;55(6):663-71. Epub 2005 Aug 13.

PMID:
16133107
6.

Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.

Wargo JA, Schumacher LY, Comin-Anduix B, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS, Ribas A.

Cancer Gene Ther. 2005 Jun;12(6):516-27.

PMID:
15775996
7.

Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy.

Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, Tchekmedyian NS, Oseguera D, Comin-Anduix B, Wargo JA, Amarnani SN, McBride WH, Economou JS, Butterfield LH.

J Immunother. 2004 Sep-Oct;27(5):354-67.

PMID:
15314544
8.

Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses.

Schumacher L, Ribas A, Dissette VB, McBride WH, Mukherji B, Economou JS, Butterfield LH.

J Immunother. 2004 May-Jun;27(3):191-200.

PMID:
15076136
9.

Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.

Ribas A, Wargo JA, Comin-Anduix B, Sanetti S, Schumacher LY, McLean C, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS.

J Immunol. 2004 Apr 15;172(8):4762-9.

10.

T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.

Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, Seja E, Todd K, Glaspy JA, McBride WH, Economou JS.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5902-8.

11.

Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.

Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS.

Clin Cancer Res. 2003 Mar;9(3):998-1008.

12.

Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines.

Ribas A, Amarnani SN, Buga GM, Butterfield LH, Dissette VB, McBride WH, Glaspy JA, Ignarro LJ, Economou JS.

Cancer Gene Ther. 2002 Nov;9(11):875-83.

13.

CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.

Ribas A, Butterfield LH, Amarnani SN, Dissette VB, Kim D, Meng WS, Miranda GA, Wang HJ, McBride WH, Glaspy JA, Economou JS.

Cancer Res. 2001 Dec 15;61(24):8787-93.

14.

alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination.

Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda GA, Glaspy JA, McBride WH, Economou JS.

Cancer Res. 2001 Dec 15;61(24):8782-6.

15.

Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein.

Meng WS, Butterfield LH, Ribas A, Heller JB, Dissette VB, Glaspy JA, McBride WH, Economou JS.

Mol Immunol. 2000 Nov;37(16):943-50.

PMID:
11395133
16.

T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.

Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, Faull K, Glaspy JA, McBride WH, Economou JS.

J Immunol. 2001 Apr 15;166(8):5300-8.

17.

Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.

Frost PJ, Butterfield LH, Dissette VB, Economou JS, Bonavida B.

J Immunol. 2001 Mar 1;166(5):3564-73.

18.

Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.

Andrews KJ, Ribas A, Butterfield LH, Vollmer CM, Eilber FC, Dissette VB, Nelson SD, Shintaku P, Mekhoubad S, Nakayama T, Taniguchi M, Glaspy JA, McBride WH, Economou JS.

Cancer Res. 2000 Nov 15;60(22):6457-64.

19.

Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice.

Ribas A, Butterfield LH, Hu B, Dissette VB, Meng WS, Koh A, Andrews KJ, Lee M, Amar SN, Glaspy JA, McBride WH, Economou JS.

Cancer Res. 2000 Apr 15;60(8):2218-24.

20.

Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells.

Ribas A, Butterfield LH, Hu B, Dissette VB, Chen AY, Koh A, Amarnani SN, Glaspy JA, McBride WH, Economou JS.

J Immunother. 2000 Jan;23(1):59-66.

PMID:
10687138
21.

Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells.

Ribas A, Butterfield LH, McBride WH, Dissette VB, Koh A, Vollmer CM, Hu B, Chen AY, Glaspy JA, Economou JS.

Cancer Gene Ther. 1999 Nov-Dec;6(6):523-36.

22.

p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma.

Vollmer CM, Ribas A, Butterfield LH, Dissette VB, Andrews KJ, Eilber FC, Montejo LD, Chen AY, Hu B, Glaspy JA, McBride WH, Economou JS.

Cancer Res. 1999 Sep 1;59(17):4369-74.

23.

Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma.

Vollmer CM Jr, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA, Economou JS.

Cancer Res. 1999 Jul 1;59(13):3064-7.

24.

Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities.

Ribas A, Bui LA, Butterfield LH, Vollmer CM, Jilani SM, Dissette VB, Glaspy JA, McBride WH, Economou JS.

Anticancer Res. 1999 Mar-Apr;19(2A):1165-70.

PMID:
10368670
25.

Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.

Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB, Lau R, Gamradt SC, Glaspy JA, McBride WH, Mukherji B, Economou JS.

J Immunol. 1998 Nov 15;161(10):5607-13.

26.

Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells.

Ribas A, Butterfield LH, McBride WH, Jilani SM, Bui LA, Vollmer CM, Lau R, Dissette VB, Hu B, Chen AY, Glaspy JA, Economou JS.

Cancer Res. 1997 Jul 15;57(14):2865-9.

27.

Long-term expression of a reporter gene from latent herpes simplex virus in the rat hippocampus.

Bloom DC, Maidment NT, Tan A, Dissette VB, Feldman LT, Stevens JG.

Brain Res Mol Brain Res. 1995 Jul;31(1-2):48-60.

PMID:
7476033
28.

Murine cytomegalovirus is present in both chronic active and latent states in persistently infected mice.

Yuhasz SA, Dissette VB, Cook ML, Stevens JG.

Virology. 1994 Jul;202(1):272-80.

PMID:
8009839
29.

Supplemental Content

Loading ...
Support Center